A5009266851- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Medical Imaging Techniques and Applications
- Boron Compounds in Chemistry
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Biotin and Related Studies
- Neuroblastoma Research and Treatments
- Click Chemistry and Applications
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- Synthesis and Biological Evaluation
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Chemical Synthesis and Analysis
- Fluorine in Organic Chemistry
- Prostate Cancer Treatment and Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Chemical Reactions and Isotopes
- Multiple Myeloma Research and Treatments
- Radioactive element chemistry and processing
- Cancer therapeutics and mechanisms
- bioluminescence and chemiluminescence research
University of Washington
2016-2025
Fred Hutch Cancer Center
2001-2013
University Hospital of Lausanne
2011
Cancer Research Center
2011
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2011
Molecular Oncology (United States)
2008-2009
National Cancer Institute
2002-2007
National Institutes of Health
2002-2007
University of California, Los Angeles
2003-2007
TRIUMF
2005
Technetium-99m labeling of antibodies has been suboptimal because low affinity adventitious binding, nonspecific labeling, and loss immunoreactivity. The diamide dithiolate ligand system (N2S2) forms highly stable, well-defined tetradentate complexes with Tc(V). Antibodies their fragments have labeled by conjugation preformed 99mTc-4,5-bis(thioacetamido)pentanoate active ester to protein amine groups give a chemically known 99mTc-N2S2 complex covalently linked antibody. Evaluations the...
We are investigating the hypothesis that biotin multimers can be used with streptavidin and monoclonal antibody conjugates in cancer pretargeting protocols to provide a method of increasing amount radioactivity bound on cells patients. As part investigation, series biotinylated Starburst dendrimers (BSBDs) have been prepared evaluated vitro vivo. In this study, new biotinidase-stabilized, water-solubilizing biotinylation reagent was reacted (PAMAM) dendrimers, generations 0, 1, 2, 3, 4. The...
An investigation has been conducted to assess the in vivo stability of a series astatinated benzamides and nido-carborane compounds mice. It was hypothesized that higher bond strength boron−astatine bonds nido-carboranes might provide increased toward deastatination. Four tri-n-butylstannylbenzamides were prepared for radiohalogenation evaluation vivo. Those N-propyl-4-(tri-n-butylstannyl)benzamide 1a, N-propyl-3-(tri-n-butylstannyl)benzamide 2a, ethyl 4-tri-n-butylstannylhippurate 3a,...
Cancer-targeting biomolecules labeled with 211At must be stable to in vivo deastatination, as control of the distribution is critical due highly toxic nature α-particle emission. Unfortunately, no astatinated aryl conjugates have shown stability toward deastatination when (relatively) rapidly metabolized proteins, such monoclonal antibody Fab' fragments, are labeled. As a means increasing 211At-labeled we been investigating boron cage moieties. In this investigation, protein-reactive...
We are investigating the use of an (211)At-labeled anti-CD45 monoclonal antibody (mAb) as a replacement total body irradiation in conditioning regimens designed to decrease toxicity hematopoietic cell transplantation (HCT). As part that investigation, dose-escalation studies were conducted dogs using anticanine CD45 mAb, CA12.10C12, conjugated with maleimido-closo-decaborate(2-) derivative, 4. Unacceptable renal was noted receiving doses 0.27-0.62 mCi/kg range. This result not anticipated,...
Purpose: Alpha‐emitting radionuclides exhibit a potential advantage for cancer treatments because they release large amounts of ionizing energy over few cell diameters (50–80 μ m), causing localized, irreparable double‐strand DNA breaks that lead to death. Radioimmunotherapy (RIT) approaches using monoclonal antibodies labeled with α emitters may thus inactivate targeted cells minimal radiation damage surrounding tissues. Tools are needed visualize and quantify the radioactivity distribution...
Abstract The use of α-emitting radionuclides in targeted alpha therapy (TAT) holds great potential for treatment human diseases, such as cancer, due to the short pathlength and high potency α particle, which can localize damage cells while minimizing effects healthy surrounding tissues. In this review several having emission properties applicable TAT are discussed from a radiochemical point view. Overviews production, separation chelation aspects relative developing radiopharmaceuticals...
The vast majority of patients with plasma cell neoplasms die progressive disease despite high response rates to novel agents. Malignant cells are very radiosensitive, but the potential role radioimmunotherapy (RIT) in management plasmacytomas and multiple myeloma has undergone only limited evaluation. Furthermore, CD38 not been explored as a RIT target its uniform expression on malignant cells. In this report, both conventional (directly radiolabeled antibody) streptavidin-biotin pretargeted...
Abstract Terbium-161 ( 161 Tb) is emerging as a promising radionuclide for cancer therapy due to its favorable nuclear properties that are similar clinically established lutetium-177 177 Lu) along with therapeutic edge arising from the higher number of Auger and conversion electrons per decay. These low energy result in cytotoxicity within short range decaying nuclei enhance efficacy. Despite these characteristics, significant challenge remains lack domestic Tb supply United States, which...